Dr Hope Rugo: Advances in HER2-Positive Breast Cancer

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses advances in the treatment of HER2-positive breast cancer.
February 07, 2018


Is there anything you’re working on or excited about in HER2-positive breast cancer that you’d like to share?

We're working on a number of different things. One is trying to move neratinib earlier in the adjuvant course and seeing if we can manage the diarrhea with a novel agent. So that’s one trial my colleague Joe Chen is working on.

In terms of the metastatic setting, there are a number of novel agents, oral TKIs [tyrosine-kinase inhibitors], and then an antibody–drug conjugate from Daiichi which has shown responses in patients who had highly resistant disease, at least as reported to trastuzumab. That’s going into a phase 3 trial this year. Then there’s a novel antibody that binds to the receptors a bit differently called margetuximab that’s in a phase 3 trial called the SOPHIA trial. That drug also showed responses in phase 1 studies in patients who had disease resistant to trastuzumab.

So, I think there’s a number of different agents out there which seem as though they have potential for the future. 



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.